00:01 , May 23, 2019 |  BioCentury  |  Finance

With new CEO, $55M A round, Locana readies RNA-targeting gene therapy for clinic

Preclinical data supporting its RNA-targeting gene therapy platform enabled Locana to attract $55 million in series A funding led by existing investor Arch Venture Partners, which the San Diego company plans to use to bring...
22:54 , May 20, 2019 |  BC Extra  |  Company News

May 20 Company Quick Takes: LifeArc trades Keytruda royalties for $1.3B; plus Evotec-Just, Actelion-Owlstone, Genomind

LifeArc gets $1.3B for Keytruda royalties  U.K. medical research charity LifeArc sold an undisclosed portion of its royalties for Keytruda pembrolizumab to a subsidiary of the Canada Pension Plan Investment Board for $1.3 billion. LifeArc...
22:23 , May 10, 2019 |  BC Extra  |  Financial News

May 10 Financial Quick Takes: Intercept raises over $400M; plus 28-7, LunaPBC

Intercept raises $410.4M via sales of stock, notes  Liver disease company Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) raised $200.4 million through the sale of 2.4 million shares at $83.50 in a follow-on, another $200 million through the...
09:59 , May 7, 2019 |  BC Innovations  |  Emerging Company Profile

Verve turns CRISPR against cardiovascular disease

Most CRISPR companies are targeting rare genetic disorders, but Verve is breaking from the trend with gene editing therapies for coronary artery disease that could have fewer side effects, greater efficacy and better compliance than...
10:08 , Apr 30, 2019 |  BioCentury  |  Finance

How Nextech-led round will help Vividion to POC

After identifying three lead programs with its proteome-wide small molecule screening platform, San Diego-based Vividion has raised $82 million in an oversubscribed series B round led by new investor Nextech Invest. Now flush with over...
14:31 , Apr 26, 2019 |  BC Extra  |  Financial News

Schizophrenia therapy developer Karuna among four biotechs to file for IPOs

Weeks after completing its $80 million series B round, antipsychotic therapy developer Karuna said it has filed confidential documentation with the SEC for a planned IPO. The company was one of four to unveil plans...
23:47 , Apr 25, 2019 |  BC Extra  |  Company News

Arch to continue investing in science-driven consumer wellness even as Arivale folds

Four years after raising a $36 million series B round led by Arch Venture Partners and Polaris Partners, scientific wellness company Arivale Inc. (Seattle, Wash.) has shuttered its consumer program, citing troubles with its business...
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
12:21 , Apr 16, 2019 |  BC Extra  |  Company News

With insitro deal, Gilead turns to machine learning to unlock new NASH targets

Not yet content with the trio of clinical programs in its pipeline, Gilead has struck its third NASH deal this year, this time banking on machine learning company insitro to develop disease models and discover...
23:14 , Apr 11, 2019 |  BC Innovations  |  Targets & Mechanisms

A venture view of biological white space

Scanning the horizon of translational research, VCs on BioCentury’s scientific advisory board see innate neuroinflammation as a white space area flush with under-tapped angles for drug development, and think the rise of single cell-level data...